Pharmacokinetics of liposomal levamisole after oral, intramuscular, and subcutaneous administration in sheep

dc.contributor.authorSusar, Hasan
dc.contributor.authorKarahan, Izzet
dc.date.accessioned2025-07-03T21:25:04Z
dc.date.issued2025
dc.departmentBalıkesir Üniversitesi
dc.description.abstractThis study aimed to determine the pharmacokinetics of free and liposomal levamisole in sheep following single oral (O), intramuscular (IM), and subcutaneous (SC) administrations at a dose of 7.5 mg/kg. The study developed a levamisole liposome and investigated relevant parameters: particle size, zeta potential, polydispersity index, encapsulation efficiency, pH, and morphology. The Bangham method, a thin-film hydration technique, was employed to prepare the liposomal levamisole. Blood samples were collected by jugular venipuncture in heparinized tubes immediately before each free and liposomal levamisole treatment and at 2.5, 5, 10, 15, 30, 60, 90, 120, 240, 360, and 480 min and 12, 16, and 24 h after O, IM, and SC administration. Free and liposomal levamisole plasma concentrations were measured using high-performance liquid chromatography ultraviolet (HPLC-UV). The pharmacokinetic study showed that the O (p: 0.036) and SC (p: 0.047) liposomal levamisole groups had higher maximum concentrations (Cmax) than the free levamisole groups. A comparison of the liposomal administration routes revealed no significant difference in Cmax between IM and SC administration. However, both methods showed better results than O administration. The last observed quantifiable concentration, area to the last experimental point, zero to infinite area, and total body clearance values were found to be better with IM administration than the other two. In conclusion, liposomal levamisole preparation provides plasma concentrations that are therapeutically effective for a longer period than free levamisole, making it more effective and convenient for treatment.
dc.description.sponsorshipTUBIdot;TAK [121O098]
dc.description.sponsorshipThe study was supported by a grant from TUB & Idot;TAK, project number 121O098. This study was produced from the doctorate thesis Liposomal levamisole
dc.identifier.doi10.55730/1300-0128.4364
dc.identifier.issn1300-0128
dc.identifier.issue1
dc.identifier.scopus2-s2.0-85219532714
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.55730/1300-0128.4364
dc.identifier.urihttps://hdl.handle.net/20.500.12462/21353
dc.identifier.volume49
dc.identifier.wosWOS:001427593100001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherTubitak Scientific & Technological Research Council Turkey
dc.relation.ispartofTurkish Journal of Veterinary & Animal Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250703
dc.subjectLevamisole
dc.subjectliposome
dc.subjectHPLC
dc.subjectpharmacokinetic parameters
dc.titlePharmacokinetics of liposomal levamisole after oral, intramuscular, and subcutaneous administration in sheep
dc.typeArticle

Dosyalar